0001883850-23-000095.txt : 20231213 0001883850-23-000095.hdr.sgml : 20231213 20231213160543 ACCESSION NUMBER: 0001883850-23-000095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231211 FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YANCOPOULOS GEORGE CENTRAL INDEX KEY: 0001226690 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 231484006 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2023-12-11 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001226690 YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 Bd. Co-Chair, President & CSO 0 Common Stock 2023-12-11 4 M 0 25155 A 765327 D Common Stock 2023-12-11 4 F 0 12841 844.09 D 752486 D Common Stock 5889 I By 401(k) Plan Common Stock 196848 I By Trust for Chldn. Common Stock 121071 I by 2022 GRAT I Common Stock 158410 I by 2022 GRAT II 2019 Performance Stock Units 2023-12-11 4 M 0 25155 D Common Stock 25155 0 D On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. As investment trustee of trusts for the benefit of the reporting person's children. /s/**George D. Yancopoulos 2023-12-13